-
Je něco špatně v tomto záznamu ?
The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus
L. Sromova, P. Busek, H. Posova, J. Potockova, P. Skrha, M. Andel, A. Sedo,
Jazyk angličtina Země Irsko
Typ dokumentu časopisecké články, pozorovací studie
Grantová podpora
NT12407
MZ0
CEP - Centrální evidence projektů
- MeSH
- diabetes mellitus 2. typu krev farmakoterapie imunologie MeSH
- dospělí MeSH
- inhibitory dipeptidylpeptidasy 4 aplikace a dávkování MeSH
- lidé MeSH
- počet lymfocytů MeSH
- regulační T-lymfocyty účinky léků imunologie MeSH
- sitagliptin fosfát aplikace a dávkování MeSH
- Th1 buňky účinky léků imunologie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
AIM: To assess intraindividually the effects of DPP-IV inhibition on the subpopulations of immune cells in type 2 diabetes mellitus (DM2) patients during the course of treatment with sitagliptin. METHODS: In this open label non-randomized observational study with a control group DM2 patients were examined before the initiation of the DPP-IV inhibitor administration (sitagliptin 100mg once daily) and then after 4weeks and 12months. Inhibition of the blood plasma DPP-IV enzymatic activity was determined by a chromogenic assay, the immunophenotyping of the blood cell subpopulations was performed using flow cytometry and blood plasma cytokine concentrations were quantified using an array-based multiplex ELISA. All parameters were evaluated in relation to the entry values in individual patients. RESULTS: The blood plasma DPP-IV enzymatic activity was effectively inhibited during the sitagliptin treatment. A significant decrease of the proportion of Treg cells (to 86±31% (median±SD) of entry values, p=0.001) and an increase of Th1 cells (to 120±103% (median±SD) of entry values, p=0.004) were observed after 4weeks but not after one year of the sitagliptin treatment. No changes were observed in the ratio of CD4(+)/CD8(+) cells, in the quantity of NK and Th2 cells and blood plasma cytokine levels. CONCLUSIONS: Sitagliptin treatment may cause temporary changes of the proportion of lymphocyte subpopulations in patients with DM2. The consequent deregulation of the immune system should be considered as a possible cause of the eventual side effects of long term DPP-IV inhibition.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17000245
- 003
- CZ-PrNML
- 005
- 20190923103637.0
- 007
- ta
- 008
- 170103s2016 ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.diabres.2016.06.020 $2 doi
- 024 7_
- $a 10.1016/j.diabres.2016.06.020 $2 doi
- 035 __
- $a (PubMed)27388675
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Stollinová Šromová, Lucie $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, U nemocnice 5, 12853 Prague 2, Czech Republic. Electronic address: lsrom@lf1.cuni.cz. $7 xx0211880
- 245 14
- $a The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus / $c L. Sromova, P. Busek, H. Posova, J. Potockova, P. Skrha, M. Andel, A. Sedo,
- 520 9_
- $a AIM: To assess intraindividually the effects of DPP-IV inhibition on the subpopulations of immune cells in type 2 diabetes mellitus (DM2) patients during the course of treatment with sitagliptin. METHODS: In this open label non-randomized observational study with a control group DM2 patients were examined before the initiation of the DPP-IV inhibitor administration (sitagliptin 100mg once daily) and then after 4weeks and 12months. Inhibition of the blood plasma DPP-IV enzymatic activity was determined by a chromogenic assay, the immunophenotyping of the blood cell subpopulations was performed using flow cytometry and blood plasma cytokine concentrations were quantified using an array-based multiplex ELISA. All parameters were evaluated in relation to the entry values in individual patients. RESULTS: The blood plasma DPP-IV enzymatic activity was effectively inhibited during the sitagliptin treatment. A significant decrease of the proportion of Treg cells (to 86±31% (median±SD) of entry values, p=0.001) and an increase of Th1 cells (to 120±103% (median±SD) of entry values, p=0.004) were observed after 4weeks but not after one year of the sitagliptin treatment. No changes were observed in the ratio of CD4(+)/CD8(+) cells, in the quantity of NK and Th2 cells and blood plasma cytokine levels. CONCLUSIONS: Sitagliptin treatment may cause temporary changes of the proportion of lymphocyte subpopulations in patients with DM2. The consequent deregulation of the immune system should be considered as a possible cause of the eventual side effects of long term DPP-IV inhibition.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a diabetes mellitus 2. typu $x krev $x farmakoterapie $x imunologie $7 D003924
- 650 _2
- $a inhibitory dipeptidylpeptidasy 4 $x aplikace a dávkování $7 D054873
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a počet lymfocytů $7 D018655
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a sitagliptin fosfát $x aplikace a dávkování $7 D000068900
- 650 _2
- $a regulační T-lymfocyty $x účinky léků $x imunologie $7 D050378
- 650 _2
- $a Th1 buňky $x účinky léků $x imunologie $7 D018417
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Bušek, Petr $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, U nemocnice 5, 12853 Prague 2, Czech Republic. Electronic address: busekpetr@seznam.cz. $7 xx0094315
- 700 1_
- $a Posová, Helena, $u Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University in Prague, Studnickova 7, 12000 Prague 2, Czech Republic. Electronic address: hmare@lf1.cuni.cz. $d 1963- $7 xx0060265
- 700 1_
- $a Potočková, Jana $u 2nd Department of Internal Medicine, 3rd Faculty of Medicine and Faculty Hospital Královské Vinohrady, Charles University in Prague, Srobarova 1150, 10034 Prague 10, Czech Republic. Electronic address: potocko@fnkv.cz. $7 xx0071181
- 700 1_
- $a Škrha, Pavel $u 2nd Department of Internal Medicine, 3rd Faculty of Medicine and Faculty Hospital Královské Vinohrady, Charles University in Prague, Srobarova 1150, 10034 Prague 10, Czech Republic. Electronic address: pavel.skrha@email.cz. $7 xx0211879
- 700 1_
- $a Anděl, Michal $u 2nd Department of Internal Medicine, 3rd Faculty of Medicine and Faculty Hospital Královské Vinohrady, Charles University in Prague, Srobarova 1150, 10034 Prague 10, Czech Republic. Electronic address: andel@fnkv.cz. $7 jn19981228006
- 700 1_
- $a Šedo, Aleksi, $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, U nemocnice 5, 12853 Prague 2, Czech Republic. Electronic address: aleksi@cesnet.cz. $d 1967- $7 jn20000605245
- 773 0_
- $w MED00001385 $t Diabetes research and clinical practice $x 1872-8227 $g Roč. 118, č. - (2016), s. 183-192
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27388675 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170103 $b ABA008
- 991 __
- $a 20190923104033 $b ABA008
- 999 __
- $a ok $b bmc $g 1179385 $s 960812
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 118 $c - $d 183-192 $e 20160618 $i 1872-8227 $m Diabetes research and clinical practice $n Diabetes Res Clin Pract $x MED00001385
- GRA __
- $a NT12407 $p MZ0
- LZP __
- $a Pubmed-20170103
